Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
暂无分享,去创建一个
M. Mohty | H. Avet-Loiseau | M. Macro | X. Leleu | J. Corre | T. Facon | T. Filleron | M. Attal | A. Jaccard | M. Roussel | A. Perrot | A. Stoppa | F. Orsini-Piocelle | S. Bréchignac | K. Belhadj | C. Hulin | D. Caillot | I. Plantier | L. Voillat | Marly Barry | E. Martin | B. Hébraud | L. Montes | J. Fontan | H. Demarquette | Didier Adiko | Faiza Keddar | Marie-Noelle Certain
[1] O. Decaux,et al. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Hari,et al. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] H. Goldschmidt,et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. , 2019, Blood.
[4] J. Harousseau,et al. How I treat first relapse of myeloma. , 2017, Blood.
[5] D. Dingli,et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents , 2016, Leukemia.
[6] M. Ooi,et al. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group , 2016, Bone Marrow Transplantation.
[7] H. Goldschmidt,et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Trudel,et al. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents , 2015, Bone Marrow Transplantation.
[9] M. Dimopoulos,et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.
[10] D. Dingli,et al. Impact of early relapse after auto-SCT for multiple myeloma , 2008, Bone Marrow Transplantation.
[11] G. Ahmann,et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. , 2005, Blood.
[12] S. Trudel,et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Crowley,et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Rue,et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.
[15] M. Terol,et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. , 2012, Blood.